title: Ranibizumab for macular telangiectasia type 2 in the absence of subretinal neovascularization.
abstract: OBJECTIVE
  To evaluate the effects of 0.3 mg or 0.5 mg of ranibizumab in eyes with macular telangiectasia type 2 without subretinal neovascularization.
  
  
  METHODS
  Ten eyes were randomized to either 0.3 mg or 0.5 mg ranibizumab group in 1 eye only. Study eye received ranibizumab at baseline and at Months 1 and 2. Injections at Months 3, 4, and 5 were at investigator's discretion. Participants were followed monthly through 6 months with best-corrected visual acuity, fluorescein angiography, and optical coherence tomography.
  
  
  RESULTS
  For study eyes at baseline, median best-corrected visual acuity letter score was 60 (20/64 Snellen equivalent) and central subfield retinal thickness was 181.5 μm. Median number of injections was six. Median change in best-corrected visual acuity at Month 3 was 4 letters (range: -5 to 9 letters) at both doses in the study eye and 3 letters (range: -10 to 5 letters) in the untreated fellow eye. At Month 3, retinal leakage decreased 0.87 disk area and 0.76 disk area for 0.3 mg and 0.5 mg ranibizumab, respectively. Median change in central subfield retinal thickness was 1 μm and -11 µm for 0.3 mg and 0.5 mg ranibizumab, respectively.
  
  
  CONCLUSIONS
  Ranibizumab (0.3 mg or 0.5 mg) decreases leakage secondary to macular telangiectasia type 2, but accompanying improvements in best-corrected visual acuity appear similar to improvements in the untreated fellow eye where retinal thickness is relatively unchanged.
authors: *Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, Nebraska; †Division of Retina, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; ‡Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; §Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, North Carolina; and ¶Retina Vitreous Associates Medical Group, Los Angeles, California.
authors: Diana V
authors: DV
authors: Do
authors: Susan B
authors: SB
authors: Bressler
authors: Sandra D
authors: SD
authors: Cassard
authors: Emily W
authors: EW
authors: Gower
authors: Homayoun
authors: H
authors: Tabandeh
authors: Joan L
authors: JL
authors: Jefferys
authors: Neil M
authors: NM
authors: Bressler
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D002199:Capillary Permeability / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D000069579:Ranibizumab; D015861:Retinal Neovascularization / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D058456:Retinal Telangiectasis / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D012171:Retinal Vessels / Q000473:pathology; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab